Adhera Therapeutics (ATRX)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

P.O. BOX 2161 WAKE FOREST, NC 27588

MDRNA, Inc. (MDRNA), formerly Nastech Pharmaceutical Company Inc., is a biotechnology company focused on the development and commercialization of therapeutic products based on ribonucleic acid interference (RNAi). The Company develops RNAi-based product candidates for the treatment of cancer, metabolic disorders, inflammation, and viral infections. It focuses on siRNA constructs, such as dicer substrates and three-stranded meroduplexes, and proprietary delivery systems for improved siRNA delivery. MDRNA's various development programs comprise: oncology; metabolic disorders, and inflammation. The Company has various therapeutic programs, such as MDR-04227 for metabolic dysfunction; MDR-09521 and MDR-09513 for oncology; MDR-06155 for inflammation and MDR-03030 for respiratory virus. It also has various products in the pipeline, which include MDRNA ONC1 for oncology; MDRNA TNF1 for inflammation; MDRNA ApoB for metabolic disorders, and MDRNA INFA for respiratory virus.

Data as of 2021-08-02 07:59:32 -0400
Market Cap2.675 Million Shares Outstanding11.631 Million Avg 30-day Volume716.937 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low0.48 / 0.015 Next Earnings Date Price to Cash FLow (P/CF) 0.0361
Data provided by IEX Cloud

Are you looking for this stock instead?

View SEC Filings from ATRX instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 3 3 0.0% (0.0%) (0.0%)
13F shares: 342 373 -8.31%
% Ownership 0.0031 0.0034 -8.82%
New Positions:
Increased Positions 1
Closed Positions
Reduced Positions 1
Total Calls
Total Puts
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ATRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ATRX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KUCHARCHUK ANDREW ALBERT CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2020-07-07 0

STANLEY RHONDA L. SVP FINANCE & ACCOUNTING

  • Officer
0 2019-11-01 0

PHELAN NANCY R. CEO AND SECRETARY

  • Officer
  • Director
0 2019-04-04 0

TEAGUE ROBERT ERIC CHIEF FINANCIAL OFFICER

  • Officer
0 2019-01-15 0

LANGER ROBERT

  • Director
11,509,357 2018-12-11 0

BANCEL STEPHANE CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
24,861,775 2018-12-11 0

RUIZ ISRAEL

  • Director
4,559 2018-12-11 0

HOGE STEPHEN PRESIDENT

  • Officer
2,100,646 2018-12-11 0

KIM LORENCE H. CHIEF FINANCIAL OFFICER

  • Officer
1,147,327 2018-12-11 0

BERENSON STEPHEN

  • Director
22,798 2018-12-11 0

NABEL ELIZABETH G

  • Director
44,344 2018-12-11 0

SAGAN PAUL

  • Director
461,429 2018-12-11 0

AFEYAN NOUBAR

FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC

FLAGSHIP PIONEERING INC.

FLAGSHIP VENTURELABS IV, LLC

FLAGSHIP VENTURES FUND IV, L.P.

FLAGSHIP VENTURES FUND IV-RX, L.P.

KANIA EDWIN M JR

  • Director
  • 10% Owner
155,251,459 2018-12-11 0

MENDLEIN JOHN SEE REMARKS

  • Officer
806,154 2018-12-07 0

ANDRES JUAN SEE REMARKS

  • Officer
0 2018-12-07 0

LEE JENNIFER LING CHIEF ACCOUNTING OFFICER

  • Officer
0 2018-12-07 0

HUTT PETER BARTON

  • Director
3,924 2018-12-07 0

ZAKS TAL ZVI CHIEF MEDICAL OFFICER

  • Officer
204,770 2018-12-07 0

HENDERSON LORI M. GENERAL COUNSEL AND SECRETARY

  • Officer
0 2018-12-07 0

SLAOUI MONCEF

  • Director
0 2018-12-07 0

TRIEU VUONG

  • Director
  • 10% Owner
3,536,813 2018-10-01 0

MOSCATO ROBERT JR. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2018-07-12 0

EMERSON ERIK CHIEF COMMERCIAL OFFICER

  • Officer
  • Director
0 2018-07-10 0

HACKSELL ULI

  • Director
0 2018-07-10 0

RANKER PHILIP C

  • FORMER DIRECTOR
No longer subject to file 2018-05-02 0

RAMELLI JOSEPH W.

  • FORMER CHIEF EXECUTIVE OFFICER
No longer subject to file 2018-05-02 0

CALAIS PHILIPPE

  • FORMER DIRECTOR
No longer subject to file 2018-05-02 0

BORIS TIMOTHY

  • Director
0 2018-04-27 0

WILLIAMS DONALD ALLEN

  • Director
0 2018-04-16 0

HWANG LARN CHIEF SCIENTIFIC OFFICER

  • Officer
0 2018-04-16 0

BLECH ISAAC

  • Director
0 2018-04-16 0

WEINSTEIN PETER D. CHIEF LEGAL OFFICER

  • Officer
0 2017-10-12 0

SHAH AMIT B. CHIEF FINANCIAL OFFICER

  • Officer
0 2017-10-02 0

MUNSIF MIHIR CHIEF OPERATING OFFICER

  • Officer
0 2017-02-13 0

LOREN STEFAN

  • Director
0 2017-01-03 0

AUTOTELIC LLC

  • 10% Owner
23,123,558 2016-11-15 0

FRENCH J MICHAEL PRESIDENT AND CEO

  • Officer
  • Director
822,283 2014-12-30 0

GEFFKEN DANIEL E. INTERIM CFO

  • Officer
0 2014-05-13 0

PRYOR CASHMAN LLP

  • 10% Owner
No longer subject to file 2014-02-06 0

HO RICHARD THEODORE EXECUTIVE VICE PRESIDENT - R&D

  • Officer
No longer subject to file 2014-01-01 0

BIOMED REALTY TRUST INC

  • 10% Owner
9,915,727 2011-09-27 0

FLETCHER R JOHN

  • Director
0 2011-09-02 0

SESSLER GREGORY

  • Director
0 2011-09-02 0

KARIS JAMES

  • Director
0 2011-09-02 0

TAYLOR MICHAEL DOUGLAS

  • Director
0 2011-09-02 0

PARKER PETER

  • Director
0 2011-09-02 0

GARCIA PETER S CHIEF FINANCIAL OFFICER

  • Officer
5,000 2011-08-26 0

POLISKY BARRY CHIEF SCIENTIFIC OFFICER

  • Officer
0 2011-08-26 0

NOVARTIS BIOVENTURES LTD

NOVARTIS AG

  • 10% Owner
No longer subject to file 2011-01-25 0

LI CHIANG J

  • Director
62,395 2010-07-21 0

THAW BRUCE R/FA

  • Director
0 2009-05-20 0

ROTHMAN JAMES

  • Director
0 2009-05-20 0

YORK BRUCE R CFO AND SECRETARY

  • Officer
0 2009-05-20 0

PETERS DANIEL

  • Director
0 2009-05-20 0

QUAY STEVEN C

  • Director
1,166,669 2009-03-16 0

COSTANTINO HENRY R CSO - DELIVERY

  • Officer
24,047 2008-08-02 0

DUFFY TIMOTHY M CHIEF BUSINESS OFFICER

  • Officer
56,395 2008-07-01 0

CROSS ALEXANDER D

  • Director
38,000 2008-06-10 0

BAYH SUSAN B

  • Director
24,735 2008-06-10 0

POLLOCK JOHN V

  • Director
30,833 2008-06-10 0

STANEWICK GERALD T

  • Director
175,412 2008-05-12 0

BRANDT GORDON PRESIDENT

  • Officer
41,705 2008-04-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ADHERA THERAPEUTICS INC ATRX 2021-08-05 22:15:04 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 21:45:03 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 21:15:03 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 20:45:03 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 20:15:04 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 19:45:04 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 19:15:03 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 18:45:03 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 18:15:03 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 17:45:03 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 17:15:03 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 16:45:02 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 16:15:03 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 15:45:03 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 15:15:02 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 14:45:02 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 14:15:04 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 13:45:04 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 13:15:03 UTC -1.2339 1.3139 15000
ADHERA THERAPEUTICS INC ATRX 2021-08-05 12:45:03 UTC -1.2339 1.3139 15000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments